Argyro Repa

1.2k total citations
47 papers, 675 citations indexed

About

Argyro Repa is a scholar working on Rheumatology, Immunology and Pathology and Forensic Medicine. According to data from OpenAlex, Argyro Repa has authored 47 papers receiving a total of 675 indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Rheumatology, 18 papers in Immunology and 10 papers in Pathology and Forensic Medicine. Recurrent topics in Argyro Repa's work include Systemic Lupus Erythematosus Research (17 papers), Rheumatoid Arthritis Research and Therapies (12 papers) and Autoimmune and Inflammatory Disorders Research (8 papers). Argyro Repa is often cited by papers focused on Systemic Lupus Erythematosus Research (17 papers), Rheumatoid Arthritis Research and Therapies (12 papers) and Autoimmune and Inflammatory Disorders Research (8 papers). Argyro Repa collaborates with scholars based in Greece, United States and Bulgaria. Argyro Repa's co-authors include Prodromos Sidiropoulos, George Βertsias, Dimitrios T. Boumpas, Antonis Fanouriakis, Christianna Choulaki, Konstantinos Kambas, Konstantinos Ritis, Nikolaos Kougkas, Christina Adamichou and Irini Gergianaki and has published in prestigious journals such as SHILAP Revista de lepidopterología, Frontiers in Immunology and Annals of the Rheumatic Diseases.

In The Last Decade

Argyro Repa

46 papers receiving 668 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Argyro Repa Greece	12	345	300	233	76	67	47	675
Е Н Александрова Russia	11	374 1.1×	161 0.5×	90 0.4×	106 1.4×	88 1.3×	210	610
Jean‐Frédéric Boyer France	10	323 0.9×	181 0.6×	109 0.5×	54 0.7×	28 0.4×	15	553
Scott E. Wenderfer United States	16	299 0.9×	297 1.0×	144 0.6×	80 1.1×	30 0.4×	60	780
Dionysis Nikolopoulos Greece	16	572 1.7×	431 1.4×	76 0.3×	53 0.7×	111 1.7×	63	779
Cheng‐Chin Wu Taiwan	14	240 0.7×	254 0.8×	180 0.8×	51 0.7×	55 0.8×	38	619
Chien‐Hsueh Tung Taiwan	15	223 0.6×	179 0.6×	157 0.7×	57 0.8×	44 0.7×	42	632
Kongyang Ma China	12	188 0.5×	418 1.4×	190 0.8×	26 0.3×	37 0.6×	27	777
Matt Cravets United States	11	330 1.0×	106 0.4×	135 0.6×	157 2.1×	147 2.2×	17	679
Lisbeth Ärlestig Sweden	18	424 1.2×	243 0.8×	158 0.7×	59 0.8×	47 0.7×	31	721
Shinya Ikoma Japan	13	205 0.6×	205 0.7×	232 1.0×	44 0.6×	33 0.5×	23	500

Countries citing papers authored by Argyro Repa

Since Specialization

Citations

This map shows the geographic impact of Argyro Repa's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Argyro Repa with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Argyro Repa more than expected).

Fields of papers citing papers by Argyro Repa

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Argyro Repa. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Argyro Repa. The network helps show where Argyro Repa may publish in the future.

Co-authorship network of co-authors of Argyro Repa

This figure shows the co-authorship network connecting the top 25 collaborators of Argyro Repa. A scholar is included among the top collaborators of Argyro Repa based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Argyro Repa. Argyro Repa is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Silvagni, Ettore, Argyro Repa, Konstantinos Parperis, et al.. (2025). Combination of clinical factors predicts successful glucocorticoid withdrawal in systemic lupus erythematosus (SLE): results from a multicentre, retrospective cohort study. RMD Open. 11(1). e005118–e005118. 3 indexed citations

Καραμανάκος, Αναστάσιος, Dimitra Koumaki, Argyro Repa, et al.. (2024). Anifrolumab for systemic lupus erythematosus with multi-refractory skin disease: A case series of 18 patients. Lupus. 33(11). 1248–1253. 3 indexed citations

Garantziotis, Panagiotis, Ettore Silvagni, Argyro Repa, et al.. (2024). Pragmatic targets for moderate/severe SLE and their implications for clinical care and trial design: sustained DORIS or LLDAS for at least 6 months is sufficient while their attainment for at least 24 months ensures high specificity for damage-free progression. Annals of the Rheumatic Diseases. 83(4). 464–474. 11 indexed citations

Bertsias, Antonios, et al.. (2024). Patterns of comorbidities differentially affect long-term functional evolution and disease activity in patients with ‘difficult to treat’ rheumatoid arthritis. RMD Open. 10(1). e003808–e003808. 14 indexed citations

Papadaki, Efrosini, Vasileios Mastorodemos, Pantelis Constantoulakis, et al.. (2023). Progressive Multifocal Leukoencephalopathy in Systemic Lupus Erythematosus: A Consequence of Patient-Intrinsic or -Extrinsic Factors?. Journal of Clinical Medicine. 12(21). 6945–6945. 5 indexed citations

Repa, Argyro, Antonios Bertsias, Jérôme Zoidakis, et al.. (2023). A Peripheral Blood Signature of Increased Th1 and Myeloid Cells Combined with Serum Inflammatory Mediators Is Associated with Response to Abatacept in Rheumatoid Arthritis Patients. Cells. 12(24). 2808–2808. 6 indexed citations

Repa, Argyro, et al.. (2023). Comorbidities Burden and Implementation of the Treat–to–Target Strategy in Predicting Real-World Patient Outcomes in Spondyloarthritides. Mediterranean Journal of Rheumatology. 34(4). 581–581. 1 indexed citations

Repa, Argyro, et al.. (2023). Distinct long-term disease activity trajectories differentiate early on treatment with etanercept in both rheumatoid arthritis and spondylarthritis patients: a prospective cohort study. Rheumatology International. 44(2). 249–261. 1 indexed citations

Papastefanakis, Emmanouil, Antonis Fanouriakis, Christina Adamichou, et al.. (2022). The relation of partners’ illness representations to the coping behaviors of patients with inflammatory rheumatic diseases through patients’ illness representation: A dyadic regulation process. Current Psychology. 42(20). 16923–16931. 1 indexed citations

10.

Repa, Argyro, et al.. (2022). POS0768 PRESENCE OF ANTI-Ro/SSA AUTOANTIBODIES, HYPOCOMPLEMENTEMIA AND PHOTOSENSITIVITY INDICATE INDIVIDUALS WITH CONNECTIVE TISSUE DISEASE FEATURES WHO ARE AT INCREASED RISK FOR TRANSITION TO SYSTEMIC LUPUS ERYTHEMATOSUS. Annals of the Rheumatic Diseases. 81. 671–671.

11.

Bertsias, Antonios, et al.. (2022). Rheumatoid arthritis patients initiating rituximab with low number of previous bDMARDs failures may effectively reduce rituximab dose and experience fewer serious adverse events than patients on full dose: a 5-year cohort study. Arthritis Research & Therapy. 24(1). 132–132. 5 indexed citations

12.

Adamichou, Christina, Dionysis Nikolopoulos, Argyro Repa, et al.. (2021). Lupus or not? SLE Risk Probability Index (SLERPI): a simple, clinician-friendly machine learning-based model to assist the diagnosis of systemic lupus erythematosus. Annals of the Rheumatic Diseases. 80(6). 758–766. 71 indexed citations

13.

Panousis, Nikolaos I., George Βertsias, Halit Ongen, et al.. (2019). Combined genetic and transcriptome analysis of patients with SLE: distinct, targetable signatures for susceptibility and severity. Annals of the Rheumatic Diseases. 78(8). 1079–1089. 85 indexed citations

14.

Kougkas, Nikolaos, et al.. (2019). The value of the 2011 ASAS classification criteria in patients with Spondyloarthritis and the prognosis of non-radiographic axial Spondyloarthritis: data from a large cohort of a tertiary referral hospital. SHILAP Revista de lepidopterología. 30(1). 51–53. 3 indexed citations

15.

Fanouriakis, Antonis, Nikolaos Kougkas, George Sourvinos, et al.. (2018). Liver safety of non-tumour necrosis factor inhibitors in rheumatic patients with past hepatitis B virus infection: an observational, controlled, long-term study.. PubMed. 36(1). 102–109. 29 indexed citations

16.

Gergianaki, Irini, Antonis Fanouriakis, Argyro Repa, et al.. (2017). Epidemiology and burden of systemic lupus erythematosus in a Southern European population: data from the community-based lupus registry of Crete, Greece. Annals of the Rheumatic Diseases. 76(12). 1992–2000. 83 indexed citations

17.

Karademas, Evangelos C., Emmanouil Papastefanakis, Argyro Repa, et al.. (2017). Adaptation to inflammatory rheumatic disease: Do illness representations predict patients’ physical functioning over time? A complex relationship. Journal of Behavioral Medicine. 41(2). 232–242. 4 indexed citations

18.

Latsoudis, Helen, Mir‐Farzin Mashreghi, Joachim R. Grün, et al.. (2016). Differential Expression of miR‐4520a Associated With Pyrin Mutations in Familial Mediterranean Fever (FMF). Journal of Cellular Physiology. 232(6). 1326–1336. 22 indexed citations

19.

Choulaki, Christianna, Argyro Repa, Konstantinos Kambas, et al.. (2015). Enhanced activity of NLRP3 inflammasome in peripheral blood cells of patients with active rheumatoid arthritis. Arthritis Research & Therapy. 17(1). 257–257. 151 indexed citations

20.

Eliopoulos, Elias, Eleni Petraki, Prodromos Sidiropoulos, et al.. (2007). Familial Mediterranean Fever in Crete: a genetic and structural biological approach in a population of ‘intermediate risk’. Clinical Genetics. 73(2). 152–159. 23 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact